Latest News
PCI Pharma Acquires Bellwyck Pharma Services to Increase Global Network of Clinical Trial Services
Thursday 13 February 2020

13 February 2020 - US-based pharmaceutical and biopharmaceutical global supply chain solutions provider PCI Pharma Services has acquired Canadian packaging and labeling company Bellwyck Pharma Services serving the clinical trial and commercial drug markets, to expand clinical trial services into Canada and Continental Europe, the company said.
Terms of the transaction were not disclosed.
The acquisition will add four GMP-compliant facilities to the PCI network in the US, Germany and Canada. With Canada and Germany ranked third and fourth in the world for total number of clinical trials, respectively.
This acquisition greatly enhances the global reach of PCI's services in key markets.
Bellwyck engaged PricewaterhouseCoopers Corporate Finance Inc. as their financial advisor on this transaction.
PCI Pharma Services, principally owned by Partners Group, provides drug development solutions that increase their products' speed to market and opportunities for commercial success.
Date Published: 13/02/2020
Target: Bellwyck Pharma Services
Country: Canada
Sector: Pharmaceuticals
Type: Corporate acquisition
Status: Closed
Buyer: PCI Pharma Services
Terms of the deal were not disclosed